NCT03578224View on ClinicalTrials.gov

Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

September 6, 2018

Primary Completion Date

August 25, 2022

Study Completion Date

August 25, 2022

Conditions
Esophagus
Interventions
PROCEDURE

Endoscopic Ultrasound-Guided Fine-Needle Aspiration (EUS-FNA)

Undergo EUS-FNA

PROCEDURE

Contrast-Enhanced Ultrasound

Undergo CEUS

PROCEDURE

Fine-Needle Aspiration

Undergo FNA

DRUG

Sonazoid (Perflubutane)

Sonazoid (ultrasound contrast agent) will be injected in 0.25 mL increments at 12, 3, 6, and 9 o'clock positions around the tumor using a 19 - 22 gauge needle system under EUS guidance

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03578224 - Contrast-Enhanced Ultrasound Identification of Sentinel Nodes in Esophageal Cancer | Biotech Hunter | Biotech Hunter